Deflazacort PCD Pharma Franchise Company

Cafoli Lifecare offers a Deflazacort range of 10 formulations across tablets and suspension, manufactured in WHO-GMP certified facilities. Distributors serving paediatric, respiratory, rheumatology and dermatology prescribers can secure district-wise monopoly franchise rights with full promotional support.

What is Deflazacort?

Deflazacort is an oral corticosteroid with potent anti-inflammatory and immunosuppressive action and a relatively favourable effect on bone and glucose metabolism compared with some older steroids. It is used across a wide range of inflammatory, allergic and autoimmune conditions, and notably in Duchenne muscular dystrophy. Reference: PubChem - Deflazacort.

Available Forms

The Cafoli Deflazacort portfolio includes oral Tablets across strengths and paediatric Suspension. Contact us for current pack presentations and combinations.

Therapeutic Applications

Deflazacort is prescribed for asthma and allergic disorders, rheumatoid arthritis and connective-tissue diseases, nephrotic syndrome, inflammatory skin conditions and Duchenne muscular dystrophy. Prescribers include paediatricians, chest physicians, rheumatologists, nephrologists and dermatologists.

Why Deflazacort is a High-Potential Molecule for Distributors

Deflazacort is increasingly preferred over older oral steroids for its steroid-sparing bone and metabolic profile, especially in children, and paediatric suspension makes it a go-to in childhood nephrotic syndrome and asthma. Broad specialty use plus long courses in chronic autoimmune disease give distributors steady, cross-specialty prescription volume.

Why Choose Cafoli Lifecare

Cafoli Lifecare offers monopoly franchise rights, WHO-GMP certified manufacturing, DCGI-approved formulations, a network of 1000+ franchise partners across India, and free promotional inputs.

References

1. PubChem: Deflazacort
2. MedlinePlus: Deflazacort
3. PubMed: deflazacort clinical use